Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
FDA approves Cytokinetics' cardiac drug MYQORZO, a key product in its pipeline. Shortly after the approval, President and CEO Robert I. Blum sells a significant amount of company stock. Both events draw attention from investors tracking Cytokinetics (NasdaqGS:CYTK) and insider activity. Cytokinetics, listed on NasdaqGS:CYTK, focuses on muscle biology and treatments for serious cardiac conditions. The FDA approval of MYQORZO adds an approved therapy to its portfolio, which had centered on research and development. For readers following the cardiac drug space, this approval comes at a time when therapies for heart conditions remain a key focus for patients, clinicians, and regulators. The CEO's stock sale following the MYQORZO approval gives investors another data point to consider when assessing Cytokinetics. Some readers may look at how the new drug, future regulatory milestones, and any further insider transactions align with their own risk tolerance and time horizon. Stay
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.MarketBeat
- Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz [Seeking Alpha]Seeking Alpha
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.MarketBeat
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 4/1/26 - Form 144
- 4/1/26 - Form 4
- 3/31/26 - Form 144
- CYTK's page on the SEC website